Sigilon Therapeutics Accounts Payable

Sigilon Therapeutics (SGTX) currently reports a accounts payable of $1.1M as of June 2023. That compares with $1.1M in the prior-year period — up 5.6% year over year. Use the charts on this page to explore Sigilon Therapeutics's accounts payable history and peer comparisons.

Sigilon Therapeutics's accounts payable increased from $1.1M to $1.1M — a 5.6% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sigilon Therapeutics reported $1.1M in accounts payable as of June 2023. That compares with $1.1M in the prior-year period — up 5.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $1.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sigilon Therapeutics, and consider following SGTX for alerts when major investors trade the stock.

Sigilon Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $1.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SGTX with unrelated industries.